Actinic (Solar) Keratosis - Pipeline Review, H1 2018

  • ID: 4491154
  • Report
  • 61 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Athenex Inc
  • LEO Pharma A/S
  • Neonc Technologies Inc
  • Novartis AG
  • Promius Pharma LLC
  • MORE
Actinic (Solar) Keratosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2018, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.

An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored.

The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 5, 4, 1, 4 and 1 respectively.

Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Athenex Inc
  • LEO Pharma A/S
  • Neonc Technologies Inc
  • Novartis AG
  • Promius Pharma LLC
  • MORE
Introduction

Report Coverage

Actinic (Solar) Keratosis - Overview

Actinic (Solar) Keratosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Actinic (Solar) Keratosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development

Athenex Inc

G&E Herbal Biotechnology Co Ltd

Laboratories Ojer Pharma SL

LEO Pharma A/S

Neonc Technologies Inc

Novartis AG

Oncology Research International Ltd

Promius Pharma LLC

Actinic (Solar) Keratosis - Drug Profiles

854-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

celecoxib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluorouracil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-695 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ingenol disoxate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LFX-453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-412 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORIL-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBT-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOR-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VDA-1102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Actinic (Solar) Keratosis - Dormant Projects

Actinic (Solar) Keratosis - Discontinued Products

Actinic (Solar) Keratosis - Product Development Milestones

Featured News & Press Releases

Feb 20, 2018: Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting

Feb 14, 2018: Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis

Dec 18, 2017: NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase II Clinical Trial of NanoPac Adding to Trials in Prostate and Ovarian Cancers

Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting

Oct 12, 2017: Vidac Pharma Reports Positive Results from Phase 2a Proof-of-Concept Trial of VDA-1102 Ointment in Actinic Keratosis

Sep 26, 2017: DFB Soria Gives Update on Enrollment in Phase 2 Clinical Trial of SOR007 (Nanoparticle Paclitaxel) Ointment for Actinic Keratosis (AK)

Sep 25, 2017: Athenex Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis

Dec 12, 2016: Vidac Pharma Phase 2 Study Of VDA-1102 In Actinic Keratosis Meets Interim Analysis Criterion

Jul 29, 2016: Vidac Pharma Announces The Innitiation Of A Phase 2 Study Of VDA-1102 Ointment In Patients With Actinic Keratosis

Jun 30, 2016: Vidac Pharma Completes Phase 1A Trial Of VDA-1102 Ointment

Feb 25, 2016: Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator

Dec 30, 2015: Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis

Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Actinic (Solar) Keratosis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Actinic (Solar) Keratosis - Pipeline by Athenex Inc, H1 2018

Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2018

Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, H1 2018

Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H1 2018

Actinic (Solar) Keratosis - Pipeline by Neonc Technologies Inc, H1 2018

Actinic (Solar) Keratosis - Pipeline by Novartis AG, H1 2018

Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, H1 2018

Actinic (Solar) Keratosis - Pipeline by Promius Pharma LLC, H1 2018

Actinic (Solar) Keratosis - Dormant Projects, H1 2018

Actinic (Solar) Keratosis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Actinic (Solar) Keratosis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Actinic (Solar) Keratosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Athenex Inc
  • G&E Herbal Biotechnology Co Ltd
  • Laboratories Ojer Pharma SL
  • LEO Pharma A/S
  • Neonc Technologies Inc
  • Novartis AG
  • Oncology Research International Ltd
  • Promius Pharma LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll